Scottish consensus statement on the role of FeNO in adult asthma.
Respir Med
; 155: 54-57, 2019 08.
Article
in En
| MEDLINE
| ID: mdl-31299469
ABSTRACT
Fractional exhaled nitric oxide (FeNO) is the only available point of care test to assess type-2 inflammation in asthma. In making a diagnosis of asthma, FeNO should be used together with blood eosinophils and spirometry, alongside a history. Raised FeNO in conjunction with blood eosinophilia are treatable traits of type 2 inflammation in asthma, which in turn may guide personalised management. A FeNO suppression test can be used to assess adherence and device use with ICS therapy. Furthermore FeNO may be used to provide feedback to patients in response to ICS, especially when spirometry is normal. FeNO may facilitate appropriate referral to secondary care for more definitive specialist investigations. In summary, FeNO is cost effective in the diagnosis and management of asthma and should be incorporated into primary and secondary care as part of routine clinical practice.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Asthma
/
Inflammation
/
Nitric Oxide
Type of study:
Diagnostic_studies
Limits:
Humans
Country/Region as subject:
Europa
Language:
En
Journal:
Respir Med
Year:
2019
Document type:
Article
Affiliation country:
United kingdom